Current uses and outcomes of hematopoietic stem cell transplantation 2012
Download
1 / 44

Current Uses and Outcomes of Hematopoietic Stem Cell Transplantation 2012 - PowerPoint PPT Presentation


  • 178 Views
  • Uploaded on

Current Uses and Outcomes of Hematopoietic Stem Cell Transplantation 2012. Summary Slides. SUM12_1.ppt. Location of Centers Participating in the CIBMTR 2012. Slide 2. SUM12_22.ppt. Transplant Activity in the U.S. 1980-2011. Transplants. Slide 3. SUM12_23.ppt.

loader
I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
capcha
Download Presentation

PowerPoint Slideshow about 'Current Uses and Outcomes of Hematopoietic Stem Cell Transplantation 2012' - miller


An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript
Current uses and outcomes of hematopoietic stem cell transplantation 2012

Current Uses and Outcomes of Hematopoietic Stem Cell Transplantation2012

Summary Slides

SUM12_1.ppt


Location of centers participating in the cibmtr 2012
Location of Centers Participating in the CIBMTR2012

Slide 2

SUM12_22.ppt


Transplant activity in the u s 1980 2011
Transplant Activity in the U.S.1980-2011

Transplants

Slide 3

SUM12_23.ppt


Allogeneic stem cell sources by recipient age 2001 2010
Allogeneic Stem Cell Sourcesby Recipient Age2001-2010

Transplants, %

Age £ 20 yrs Age > 20 yrs

Slide 4

SUM12_24.ppt


Autologous stem cell sources by recipient age 2001 2010
Autologous Stem Cell Sourcesby Recipient Age, 2001-2010

Transplants, %

Age £ 20 yrs Age > 20 yrs

Slide 5

SUM12_25.ppt


Trends in transplants by type and recipient age 2001 2010
Trends in Transplantsby Type and Recipient Age*2001-2010

Transplants, %

Allogeneic TransplantsAutologous Transplants

* Transplants for AML, ALL, NHL, Hodgkin Disease, Multiple Myeloma

Slide 6

SUM12_26.ppt


Trends in transplants by transplant type and recipient age 1990 2010
Trends in Transplantsby Transplant Type and Recipient Age*1990-2010

Transplants, %

Allogeneic TransplantsAutologous Transplants

* Transplants for AML, ALL, NHL, Hodgkin Disease, Multiple Myeloma

Slide 7

SUM12_27.ppt


Current uses and outcomes of hematopoietic stem cell transplantation 2012

Indications for Hematopoietic Stem Cell Transplants in the United States, 2010(Inflation factor: Auto=1.25 (80%), Allo=1.05 (95%), All Transplants)

Number of Transplants

Slide 8

SUM12_28.ppt


Current uses and outcomes of hematopoietic stem cell transplantation 2012

Indications for Hematopoietic Stem Cell Transplants for Age £ 20yrs, in the U.S., 2010(Inflation factor: Auto=1.25 (80%), Allo=1.05 (95%), All Transplants)

Number of Transplants

Slide 9

SUM12_29.ppt


Current uses and outcomes of hematopoietic stem cell transplantation 2012
Allogeneic Transplants for Age £ 20yrs,Registered with the CIBMTR, 1993-2010- by Donor Type and Graft Source -

Number of Transplants

Slide 10

SUM12_30.ppt


Current uses and outcomes of hematopoietic stem cell transplantation 2012
Allogeneic Transplants for Age > 20yrs,Registered with the CIBMTR, 1993-2010- by Donor Type and Graft Source -

Number of Transplants

Slide 11

SUM12_31.ppt


Unrelated donor stem cell sources by recipient age 2001 2010
Unrelated Donor Stem Cell Sourcesby Recipient Age2001-2010

Transplants, %

Age £ 20 yrs Age > 20 yrs

Slide 12

SUM12_32.ppt


Unrelated cord blood transplants by age registered with the cibmtr 2001 2010
Unrelated Cord Blood Transplants by AgeRegistered with the CIBMTR2001-2010

Number of Transplants

*

* Data incomplete

Slide 13

SUM12_33.ppt


Current uses and outcomes of hematopoietic stem cell transplantation 2012
One-year Survivalby Year of Transplant, Donor and Age, Worldwide, 1997-2010- In any remission, Acute Leukemia, CML or MDS-

One-Year Survival, %

Slide 14

SUM12_34.ppt


100 day mortality after autologous transplants 2010
100-day Mortality after Autologous Transplants, 2010

Mortality, %

Slide 15

SUM12_35.ppt


100 day mortality after hla identical sibling transplants 2010
100-day Mortality after HLA-identical Sibling Transplants,2010

Early Disease

Intermediate Disease

Advanced Disease

Chronic Phase

Accelerated Phase

Blast Phase

Other

Mortality, %

Slide 16

SUM12_36.ppt


100 day mortality after unrelated donor transplants 2008 2009
100-day Mortality after Unrelated Donor Transplants,2008-2009

Early Disease

Intermediate Disease

Advanced Disease

Chronic Phase

Accelerated Phase

Blast Phase

Other

Mortality, %

Slide 17

SUM12_37.ppt


Causes of death after transplants done in 2009 2010
Causes of Death after Transplants Done in2009-2010

HLA-identical Sibling

Primary Disease (49%)

New Malignancy (1%)

GVHD (16%)

Unrelated Donor

Infection (13%)

Primary Disease

(37%)

New Malignancy (1%)

Organ Failure (5%)

Other (16%)

GVHD (18%)

Autologous

Primary Disease (72%)

New Malignancy (1%)

Infection (7%)

Infection (18%)

Other (18%)

Organ Failure (3%)

Organ Failure (8%)

Other (17%)

Slide 18

SUM12_38.ppt


Allogeneic transplants registered with the cibmtr 2001 2010 by conditioning regimen intensity age
Allogeneic TransplantsRegistered with the CIBMTR, 2001-2010 - by Conditioning Regimen Intensity & Age -

Number of Transplants

*

* Data incomplete

Slide 19

SUM12_39.ppt


Current uses and outcomes of hematopoietic stem cell transplantation 2012
Allogeneic Transplants after Reduced-intensity Conditioning, by Donor Type, Registered with CIBMTR1998-2010

Number of Transplants

Slide 20

SUM12_40.ppt


Current uses and outcomes of hematopoietic stem cell transplantation 2012
Percentage of Reduced Intensity Conditioning by Donor Type, Allo-HCTs, Registered with CIBMTR, 1998-2010- by Year of Transplant & Disease -

Reduced Intensity Conditioning,%

Slide 21

SUM12_41.ppt


Indications for hematopoietic stem cell transplants for age 5 0yrs in the u s 2010
Indications for by Donor Type, Hematopoietic Stem Cell Transplants for Age ³ 50yrs, in the U.S., 2010

Number of Transplants

Slide 22

SUM12_42.ppt


Allogeneic transplants in the u s registered with the cibmtr 2007 2011 by donor type
Allogeneic Transplants in the U.S., by Donor Type, Registered with the CIBMTR, 2007-2011 - by Donor Type -

Transplants, %

Slide 23

SUM12_43.ppt


Hematopoietic cell transplant comorbid index of u s transplant recipients by group age 2008 2011
Hematopoietic Cell Transplant Comorbid Index of U.S. Transplant Recipientsby Group Age2008-2011

Transplants, %

Slide 24

SUM12_44.ppt


Current uses and outcomes of hematopoietic stem cell transplantation 2012
Probability of Survival after HLA-identical Sibling Donor Transplants for AML, 2000-2010- By Disease Status -

100

100

90

90

80

80

70

70

60

60

Early (N=7,210)

Probability of Survival, %

50

50

40

40

Intermediate (N=1,906)

30

30

20

20

Advanced (N=2,923)

10

10

P < 0.0001

0

0

1

3

0

2

4

5

6

Years

Slide 25

SUM12_2.ppt


Probability of survival after unrelated donor transplants for aml 2000 2010 by disease status
Probability of Survival after Unrelated Donor Transplants for AML, 2000-2010- By Disease Status -

100

100

90

90

80

80

70

70

60

60

Probability of Survival, %

50

50

Early (N=5,364)

40

40

Intermediate (N=3,374)

30

30

20

20

Advanced (N=3.702)

10

10

P < 0.0001

0

0

1

3

0

2

4

5

6

Years

Slide 26

SUM12_3.ppt


Current uses and outcomes of hematopoietic stem cell transplantation 2012
Survival after HLA-identical Sibling Donor Transplants for AML, Age <20 yrs, 2000-2010- by Disease Status -

100

100

90

90

80

80

70

70

Early (N=1,292)

60

60

Probability of Survival, %

50

50

Intermediate (N=268)

40

40

30

30

Advanced (N=270)

20

20

10

10

P < 0.0001

0

0

1

3

0

2

4

5

6

Years

Slide 27

SUM12_4.ppt


Probability of survival after autologous transplants for aml 2000 2010 by disease status
Probability of Survival after Autologous Transplants for AML, 2000-2010- by Disease Status -

100

100

90

90

80

80

70

70

60

60

Intermediate (N=735)

Probability of Survival, %

50

50

40

40

Early (N=2,139)

30

30

20

20

Advanced (N=152)

10

10

P < 0.0001

0

0

1

3

0

2

4

5

6

Years

Slide 28

SUM12_5.ppt


Current uses and outcomes of hematopoietic stem cell transplantation 2012
Probability of Survival after Allogeneic Transplants for MDS, 2000-2010- by Disease Status and Donor Type -

100

100

90

90

80

80

70

70

Early, sibling donor (N=750)

60

60

Early, unrelated

donor (N=890)

Probability of Survival, %

50

50

40

40

Advanced, unrelated donor (N=1,660)

30

30

20

20

Advanced, sibling donor (N=1,407)

10

10

P < 0.0001

0

0

1

3

0

2

4

5

6

Years

Slide 29

SUM12_6.ppt


Current uses and outcomes of hematopoietic stem cell transplantation 2012
Survival after HLA-identical Sibling Donor Transplants for ALL, Age < 20 yrs,2000-2010- by Disease Status -

100

100

90

90

80

80

70

70

Early (N=849)

60

60

Probability of Survival, %

50

50

Intermediate (N=1,203)

40

40

30

30

20

20

Advanced (N=210)

10

10

P < 0.0001

0

0

1

3

0

2

4

5

6

Years

Slide 30

SUM12_7.ppt


Current uses and outcomes of hematopoietic stem cell transplantation 2012
Probability of Survival after Unrelated Donor Transplants for ALL, Age < 20 yrs, 2000-2010- By Disease Status -

100

100

90

90

80

80

70

70

Early (N=977)

60

60

Probability of Survival, %

50

50

40

40

Intermediate (N=2,034)

30

30

20

20

Advanced (N=289)

10

10

P < 0.0001

0

0

1

3

0

2

4

5

6

Years

Slide 31

SUM12_8.ppt


Current uses and outcomes of hematopoietic stem cell transplantation 2012
Survival after HLA-identical Sibling Donor Transplants for ALL, Age ³ 20 yrs, 2000-2010- By Disease Status -

100

100

90

90

80

80

70

70

60

60

Early (N=2,214)

Probability of Survival, %

50

50

40

40

Intermediate (N=715)

30

30

20

20

Advanced (N=584)

10

10

P < 0.0001

0

0

1

3

0

2

4

5

6

Years

Slide 32

SUM12_9.ppt


Current uses and outcomes of hematopoietic stem cell transplantation 2012
Probability of Survival after Unrelated Donor Transplants for ALL, Age ³ 20 yrs, 2000-2010- By Disease Status -

100

100

90

90

80

80

70

70

60

60

Early (N=1,818)

Probability of Survival, %

50

50

40

40

30

30

Intermediate (N=1,075)

20

20

10

10

Advanced (N=767)

P < 0.0001

0

0

1

3

0

2

4

5

6

Years

Slide 33

SUM12_10.ppt


Current uses and outcomes of hematopoietic stem cell transplantation 2012
Probability of Survival after HLA-identical Sibling Donor Transplants for CML, 1998-2010- By Disease Status and Transplant Year -

100

100

90

90

80

80

CP, 2001-2010 (N=2,498)

70

70

CP, 1998-2000 (N=2,239)

60

60

AP, 2001-2010 (N=360)

Probability of Survival, %

50

50

40

40

AP, 1998-2000 (N=291)

30

30

20

20

10

10

P < 0.0001

0

0

1

3

0

2

4

5

6

Years

Slide 34

SUM12_11.ppt


Current uses and outcomes of hematopoietic stem cell transplantation 2012

Survival after Autologous and HLA-matched Sibling Donor Hematopoietic Cell Transplants for CLL, 2000-2010- by Donor Type and Conditioning Regimen Intensity -

100

100

90

90

Autologous transplant (N=270)

80

80

70

70

60

60

Probability of Survival, %

50

50

Myeloablativeconditioning (N=450)

40

40

Reduced-intensity conditioning (N=871)

30

30

20

20

10

10

P < 0.0001

0

0

1

3

0

2

4

5

6

Years

Slide 35

SUM12_12.ppt


Probability of survival after allogeneic transplants for saa 2000 2010 by donor type and age
Probability of Survival after Allogeneic Transplants for SAA, 2000-2010- By Donor Type and Age -

100

100

£ 20y, Sibling Donor (N=1,375)

90

90

80

80

> 20y, Sibling Donor (N=1,425)

70

70

£ 20y, Unrelated Donor (N=654)

60

60

> 20y, Unrelated Donor (N=634)

Probability of Survival, %

50

50

40

40

30

30

20

20

10

10

P < 0.0001

0

0

1

3

0

2

4

5

6

Years

Slide 36

SUM12_13.ppt


Current uses and outcomes of hematopoietic stem cell transplantation 2012
Probability of Survival after Autologous Transplants for Hodgkin Disease, 2000-2010- By Disease Status -

100

100

90

90

CR (N=2,907)

80

80

70

70

60

60

Not in CR, sensitive (N=3,832)

Probability of Survival, %

50

50

Not in CR, resistant (N=1,237)

40

40

30

30

20

20

10

10

P < 0.0001

0

0

1

3

0

2

4

5

6

Years

Slide 37

SUM12_14.ppt


Current uses and outcomes of hematopoietic stem cell transplantation 2012
Probability of Survival after Allogeneic Transplants for Hodgkin Disease, 2000-2010- By Conditioning Regimen and Donor Type -

100

100

90

90

80

80

70

70

60

60

Probability of Survival, %

50

50

Sibling Donor (N=356)

40

40

30

30

Unrelated Donor (N=205)

20

20

10

10

P = 0.226

0

0

1

3

0

2

4

5

6

Years

Slide 38

SUM12_15.ppt


Survival after autologous transplants for follicular lymphoma 2000 2010 by disease status
Survival after Autologous Transplants for Follicular Lymphoma, 2000-2010- By Disease Status -

100

100

90

90

80

80

Sensitive (N=2,676)

70

70

60

60

Probability of Survival, %

50

50

Resistant (N=279)

40

40

30

30

20

20

10

10

P < 0.0001

0

0

1

3

0

2

4

5

6

Years

Slide 39

SUM12_16.ppt


Current uses and outcomes of hematopoietic stem cell transplantation 2012
Probability of Survival after Allogeneic and HLA-identical Sibling Transplants for Follicular Lymphoma, 2000-2010- By Disease Status -

100

100

90

90

80

80

Sensitive (N=840)

70

70

60

60

Probability of Survival, %

50

50

Resistant (N=212)

40

40

30

30

20

20

10

10

P = 0.002

0

0

1

3

0

2

4

5

6

Years

Slide 40

SUM12_17.ppt


Current uses and outcomes of hematopoietic stem cell transplantation 2012
Probability of Survival after Autologous Transplants for Diffuse Large B-Cell Lymphoma, 2000-2010- By Disease Status -

100

100

90

90

80

80

70

70

Sensitive (N=8,891)

60

60

Probability of Survival, %

50

50

40

40

30

30

Resistant (N=1,033)

20

20

10

10

P < 0.0001

0

0

1

3

0

2

4

5

6

Years

Slide 41

SUM12_18.ppt


Current uses and outcomes of hematopoietic stem cell transplantation 2012
Probability of Survival after HLA-identical Sibling Transplants for Diffuse Large B-Cell Lymphoma, 2000-2010- By Disease Status -

100

100

90

90

80

80

70

70

60

60

Probability of Survival, %

50

50

Sensitive (N=503)

40

40

30

30

20

20

Resistant (N=219)

10

10

P < 0.0001

0

0

1

3

0

2

4

5

6

Years

Slide 42

SUM12_19.ppt


Probability of survival after transplants for mantle cell lymphoma 2000 2010 by donor type
Probability of Survival after Transplants for Mantle Cell Lymphoma, 2000-2010- By Donor Type -

100

100

90

90

80

80

70

70

Autologous (3,173)

60

60

Probability of Survival, %

50

50

Sibling donor (N=554)

40

40

30

30

Unrelated donor (N=389)

20

20

10

10

P < 0.0001

0

0

1

3

0

2

4

5

6

Years

Slide 43

SUM12_20.ppt


Probability of survival after transplants for multiple myeloma 2000 2010 by donor type
Probability of Survival after Transplants Lymphoma, 2000-2010for Multiple Myeloma, 2000-2010- By Donor Type -

100

100

90

90

80

80

Autologous (N27,979)

70

70

60

60

Probability of Survival, %

50

50

40

40

Sibling Donor (N=892)

30

30

20

20

Unrelated donor (N=380)

10

10

P < 0.0001

0

0

1

3

0

2

4

5

6

Years

Slide 44

SUM12_21.ppt